Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
167.80
-0.96 (-0.57%)
: $167.48 -0.32 (-0.19%)
Products

Protagonist Therapeutics Announces The Selection Of Oral Peptide PN-235 Into Phase 2 Clinical Development Program For Multiple Indications

Published: 12/02/2021 21:18 GMT
Johnson & Johnson (JNJ) - Protagonist Therapeutics Announces the Selection of Oral Peptide Pn-235 Into Phase 2 Clinical Development Program for Multiple Indications.
Protagonist Therapeutics Inc - Pn-235 (jnj-77242113) Now Expected to Advance Into Multiple Phase 2 Clinical Studies in 2022.
Protagonist Therapeutics - Further Development of Pn-232 (jnj-7510586) Will Be Discontinued in Favor of Pn-235 Based on Its Superior Potency.
Protagonist Therapeutics -further Pn-232 Development to Be Discontinued in Favor of Pn-235 Based on Overall Pharmacokinetic, Pharmacodynamic Profile.
Protagonist Therapeutics Inc - Will Earn a $25 Million Milestone in Connection With Initiation of First Phase 2 Study of Pn-235 in Psoriasis in Early 2022.